Sort
82,697 grants matching “vaccine development”
EVALUATION OF TREATMENT STRATEGIES TO REDUCE DRUG CRAVING AND HARM IN PEOPLE WITH OPIOID USE DISORDER
$2,039,327Marie Coolahan · University Of Maryland Baltimore · N01 · FY2019 · AI
Seattle-Lausanne-Kampala CTU
$2,039,318Margaret Juliana McElrath · Fred Hutchinson Cancer Research Center · UM1 · FY2014 · AI
University of Washington (UW) Sexually Transmitted Infections (STI) Cooperative Research Center (CRC) - Syphilis Vaccine to Protect against Local and Disseminated T. pallidum Infection
$2,038,924Anna Wald · University Of Washington · U19 · FY2022 · AI
THE IMPACTA PERU CLINICAL TRIALS UNIT
$2,037,651Jorge Luis Sanchez · Asociacion Civil Impacta Salud Y Educacn · U01 · FY2010 · AI
Epithelial Ovarian Cancer Program Project
$2,037,296David R Spriggs · Sloan-Kettering Inst Can Research · P01 · FY2008 · CA
Cancer Immunotherapy Trials Network Central Operations and Statistical Center
$2,037,244Martin Cheever · Fred Hutchinson Cancer Research Center · U01 · FY2016 · CA
PATHOGENESIS AND TREATMENT OF ACUTE HIV INFECTION
$2,037,176Massachusetts General Hospital · U01 · FY2005 · AI
UCSD Department of Medicine HIV/AIDS Clinical Trials Unit
$2,036,987Constance Ann Benson · University Of California, San Diego · U01 · FY2007 · AI
Duke SPORE in Brain Cancer
$2,036,564John H Sampson · Duke University · P50 · FY2016 · CA
Malaria Vaccine: Pfs25-rEPA
$2,036,508Patrick Duffy · National Institute Of Allergy And Infectious Diseases · ZIA · FY2010 · AI
Center/Coordination, Analysis and Management/MACS
$2,036,472Lisa P Jacobson · Johns Hopkins University · UM1 · FY2013 · AI
Immunology And Pathology Of Murine Leukemia Virus Infections
$2,036,332Kim Hasenkrug · Niaid Extramural Activities · Z01 · FY2007 · AI
Preclinical Development and Clinical Proof of Concept of a Synthetic Nanoparticle
$2,035,915Lloyd Patrick Johnston · Selecta Biosciences, Inc. · U01 · FY2016 · DA
Novel Adjuvants/Delivery Systems for Biodefense Vaccines
$2,035,822Novartis Vaccines And Diagnostics, Inc. · U01 · FY2004 · AI
Task V11: General Safety Toxicity Testing
$2,035,442Thomas Rudge · Battelle Centers/Pub Hlth Res & Evaluatn · N01 · FY2023 · AI
Host and Viral Genetics Core
$2,035,081Beatrice H Hahn · Duke University · U19 · FY2006 · AI
Host and Viral Genetics Core
$2,035,081Duke University · U01 · FY2005 · AI
Paramyxoviruses as Vaccine Vectors Against Highly Pathogenic Viruses
$2,034,822Peter Leon Collins · National Institute Of Allergy And Infectious Diseases · Z01 · FY2008 · AI
CoVPN 3006: A randomized controlled study to assess SARS-CoV-2 infection, viral shedding, and subsequent potential transmission in university students immunized with Moderna COVID-19 Vaccine
$2,034,708Peter B. Gilbert · Fred Hutchinson Cancer Research Center · UM1 · FY2021 · AI
Model Systems Core (MODS Core)
$2,034,255Sallie R. Permar · Weill Medical Coll Of Cornell Univ · P01 · FY2025 · AI
Immunologic Approaches to Ovarian Cancer
$2,033,832David R Spriggs · Sloan-Kettering Inst Can Research · P01 · FY2016 · CA
Immunologic Approaches to Ovarian Cancer
$2,033,832Paul J Sabbatini · Sloan-Kettering Inst Can Research · P01 · FY2017 · CA
Immunologic Approaches to Ovarian Cancer
$2,033,832Paul J Sabbatini · Sloan-Kettering Inst Can Research · P01 · FY2018 · CA
Role of unique ADP-ribosylating vacuolating Mycoplasma pneumoniae toxin i
$2,033,593Joel Barry Baseman · University Of Texas Hlth Science Center · U19 · FY2012 · AI
Vaccination against mucosal HIV clade C transmission
$2,033,575Ruth Margrit Ruprecht · Dana-Farber Cancer Inst · P01 · FY2011 · AI